The plasma fractionation market revolves around the process of separating blood plasma into its therapeutic components—such as immunoglobulins, clotting factors, albumin, and protease inhibitors—for treating a variety of conditions like immune deficiencies, bleeding disorders, and neurological and pulmonary diseases. The market is expanding steadily, driven by rising prevalence of autoimmune and hematological disorders, growing geriatric populations, and increased healthcare access globally. North America holds a dominant position due to strong collection networks and advanced infrastructure, while Asia-Pacific is emerging rapidly thanks to expanding plasma collection and manufacturing capabilities. Continuing challenges include high cost, complex manufacturing requirements, supply limitations of donor plasma, and competition from recombinant alternatives.
According to Fortune Business Insights, the global plasma fractionation market was valued at USD 37.31 billion in 2024 and is projected to grow from USD 40.27 billion in 2025 to USD 72.45 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.8% during the forecast period. In 2024, North America dominated the market with a 56.18% share.
This report provides comprehensive intelligence on the plasma fractionation industry, including:
Leading companies such as CSL Behring, Grifols, Takeda, Octapharma, Kedrion, and others are driving the competitive dynamics through capacity expansion, partnerships, and regulatory approvals